Last reviewed · How we verify

E. coli Asparaginase, PEG-L-asparaginase

St. Jude Children's Research Hospital · Phase 3 active Small molecule

E. coli Asparaginase, PEG-L-asparaginase is a Asparaginase enzyme Small molecule drug developed by St. Jude Children's Research Hospital. It is currently in Phase 3 development for Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Lymphoma.

PEG-L-asparaginase depletes the amino acid asparagine in leukemic cells, which cannot synthesize their own asparagine and thus undergo apoptosis.

PEG-L-asparaginase depletes the amino acid asparagine in leukemic cells, which cannot synthesize their own asparagine and thus undergo apoptosis. Used for Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Lymphoma.

At a glance

Generic nameE. coli Asparaginase, PEG-L-asparaginase
SponsorSt. Jude Children's Research Hospital
Drug classAsparaginase enzyme
TargetAsparagine (amino acid substrate)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Leukemic blasts are auxotrophic for asparagine and depend on exogenous sources, making them selectively vulnerable to asparagine depletion. The PEG conjugation extends the drug's half-life and reduces immunogenicity compared to native asparaginase.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about E. coli Asparaginase, PEG-L-asparaginase

What is E. coli Asparaginase, PEG-L-asparaginase?

E. coli Asparaginase, PEG-L-asparaginase is a Asparaginase enzyme drug developed by St. Jude Children's Research Hospital, indicated for Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Lymphoma.

How does E. coli Asparaginase, PEG-L-asparaginase work?

PEG-L-asparaginase depletes the amino acid asparagine in leukemic cells, which cannot synthesize their own asparagine and thus undergo apoptosis.

What is E. coli Asparaginase, PEG-L-asparaginase used for?

E. coli Asparaginase, PEG-L-asparaginase is indicated for Acute lymphoblastic leukemia (ALL), Acute myeloid leukemia (AML), Lymphoma.

Who makes E. coli Asparaginase, PEG-L-asparaginase?

E. coli Asparaginase, PEG-L-asparaginase is developed by St. Jude Children's Research Hospital (see full St. Jude Children's Research Hospital pipeline at /company/st-jude-children-s-research-hospital).

What drug class is E. coli Asparaginase, PEG-L-asparaginase in?

E. coli Asparaginase, PEG-L-asparaginase belongs to the Asparaginase enzyme class. See all Asparaginase enzyme drugs at /class/asparaginase-enzyme.

What development phase is E. coli Asparaginase, PEG-L-asparaginase in?

E. coli Asparaginase, PEG-L-asparaginase is in Phase 3.

What are the side effects of E. coli Asparaginase, PEG-L-asparaginase?

Common side effects of E. coli Asparaginase, PEG-L-asparaginase include Hypersensitivity reactions, Pancreatitis, Hepatotoxicity, Coagulopathy, Hyperglycemia, Nausea and vomiting.

What does E. coli Asparaginase, PEG-L-asparaginase target?

E. coli Asparaginase, PEG-L-asparaginase targets Asparagine (amino acid substrate) and is a Asparaginase enzyme.

Related